Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1997
Business Overview: Neurocrine is engaged in the discovery and development of novel pharmaceutical products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances and collaborative research agreements for funding. As of March 31, 1997, the company held a cumulative deficit of approximately $5.9 million.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Total Revenues | $8,853,891 | $2,158,978 |
| Net Income | $4,141,382 | $24,666 |
| Net Income Per Share | $0.23 | $0.00 (approx) |
| Operating Expenses | $5,733,627 | $2,365,281 |
| Cash & Cash Equivalents (End of Period) | $7,218,310 | $37,504 |
| Short-term Investments | $64,611,999 | $58,594,853 |
| Total Liquidity (Cash + ST Investments) | $71,830,309 | $58,632,357 |
| Net Cash from Operating Activities | $2,325,986 | ($2,647,449) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased to $8.9 million from $2.2 million year-over-year. This was driven primarily by a $5.0 million milestone payment recognized under a collaboration with Eli Lilly and increased sponsored research revenue.
- Profitability: The company transitioned from a net loss of $206,303 in Q1 1996 to a net income of $4.1 million in Q1 1997, largely due to the milestone revenue and increased interest income ($923k vs $259k).
- Expense Growth: Operating expenses more than doubled to $5.7 million. Research and Development (R&D) expenses rose to $4.6 million (from $1.8 million) due to increased personnel and clinical development activities. General and Administrative expenses increased to $1.1 million.
- Liquidity Position: Cash and short-term investments totaled $71.8 million at March 31, 1997, a significant increase from the prior year, bolstered by operating cash flow and investment income.
Outlook, Risks, and Management Commentary
- Capital Resources: Management believes existing capital resources, interest income, and future collaboration payments will satisfy funding requirements through at least the year 2000. However, no assurance is given that these resources will be sufficient to conduct all planned R&D programs.
- Future Funding Needs: The company expects to incur substantial additional operating losses in the future as R&D and clinical trial activities expand. It may need to access public or private equity markets or seek additional strategic alliances.
- Real Estate Transaction: In February 1997, the company entered an agreement to purchase land in San Diego with a $250,000 escrow deposit, intending to sell the property to a developer for a leaseback arrangement. Cancellation of this agreement could result in forfeiture of the deposit.
- Risks: Significant risks include the uncertainty of clinical trials, regulatory approvals, patent enforcement, and the potential failure of product candidates to reach the market. Quarterly results are subject to substantial fluctuations due to the timing of milestone payments.
Investor Verification Checklist
- Milestone Dependency: Verify the sustainability of revenue streams, as the Q1 1997 profit was heavily driven by a one-time $5.0 million milestone payment from Eli Lilly.
- Burn Rate vs. Runway: Confirm the company's projected cash burn rate against its $71.8 million liquidity to validate the "through 2000" funding claim.
- Real Estate Contingency: Review the terms of the San Diego land purchase agreement and the risks associated with the $250,000 escrow deposit.
- Subsidiary Assets: Note that approximately $8.0 million in cash is held by the Canadian subsidiary (NPI Inc.), which is not consolidated but available for specific research programs.
- EPS Calculation: Be aware that the company will adopt FASB Statement No. 128 in December 1997, which will change the method for computing earnings per share (Basic EPS would be $0.25 for Q1 1997 under the new method).